Table 1. Urinary cfDNA methylation panels and clinical utilities for urothelial carcinoma.

Cancer type	Cohort	Sample	Method	Target	Sensitivity	Specificity	Reference
UBC	46 UBC, 39 hematuria	Urinary cfDNA	GWBS	GWBS	93.5%	95.8%	(78)
UBC	263 urine samples	Urinary cfDNA	PCR, MSP	FGFR3 mutation SEPTIN9, HS3ST2 and SLIT2	–	–	(84)
UBC	14 UBC, 12 hematuria	Urine pellet, urinary cfDNA	MSP	GHSR/MAL	AUC: 0.83	–	(85)

GWBS, genome wide bisulfite sequence.